Table 2. Cytogenetics and molecular information on AML patients studied.

miR-3151 and BAALC expression was determined in all patients by qRT-PCR before and after forced expression of miR-3151/BAALC. Median expression before forced expression was used to divide the patient cells into high- and low-expressing groups. Primary blasts of AML patients 1, 2, 3, and 4 were used for further in vitro studies. FLT3-ITD, internal tandem duplications in the gene encoding fms-related tyrosine kinase 3, mutated (ITD-positive) versus wild type (ITD-negative); NPM1, gene encoding nucleophosmin; n.a., not applicable; WT, wild type.

Cells	Cytogenetics	FLT3-ITD	NPM1	miR-3151/BAALC expression at diagnosis (high versus low)	miR-3151/BAALC expression after forced expression (high versus low)
AML patients
1	Normal	Mutated	WT	Low	High
2	Normal	Mutated	WT	High	High
3	Normal	WT	Mutated	High	High
4	Normal	Mutated	WT	High	High
5	Normal	WT	Mutated	Low	n.a.
6	Normal	WT	Mutated	Low	n.a.
7	Normal	Mutated	Mutated	High	n.a.
8	Normal	WT	Mutated	Low	n.a.
Cell lines
KG1a	n.a.			High	n.a.
MV4-11	n.a.			Low	High
KG1	n.a.			Low	High